In early June, PatientWorthy wrote about a group of patients called "long haulers." These people, some healthy and some with pre-existing conditions, experienced extended COVID-19 symptoms, sometimes for months after…
Last week, biotechnology company Triplet Therapeutics announced their participation in END-DM1, a natural history study to learn more about myotonic dystrophy. There are two major forms of myotonic dystrophy, a rare…
by Lauren Taylor from In The Cloud Copy Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects a patient’s joints, in addition to causing damage to the skin, eyes,…
COVID-19 turned our worlds upside down back in March, and it has been the main focus for many medical professionals since. Because it is a novel coronavirus, we did not,…
Last week, biopharmaceutical company Deciphera Pharmaceuticals announced results from its Phase 1 clinical trial on QINLOCK (ripretinib). The study, published in the Journal of Clinical Oncology, tested QINLOCK as a potential…
In a recent press release, biopharmaceutical company Aligos Therapeutics announced that the first patient was dosed in their Phase 1a/b clinical trial. The trial is designed to assess ALG-010133 as…
If you had told me in March, when the viral pandemic began, that we'd still be staying inside 5 months later, I wouldn't believe you. Yet COVID-19 has become one…
Dr. Harvey Moldofsky Harvey Moldofsky is a professor emeritus at the University of Toronto. His area of focus is SARS, and since the onset of COVID-19, he has been fully…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
